Loading
Giving a second ADC with the same kind of payload straight after the first often does not work well.
This caution pairing concerns giving a second antibody-drug conjugate with a topoisomerase 1 payload straight after a first, for example Sacituzumab govitecan after Trastuzumab deruxtecan, in Triple-negative breast cancer (TNBC) and HR-positive / HER2-negative breast cancer. Payload resistance (SLFN11 loss, TOP1 mutations, ABCG2 efflux) is shared across TOP1 ADCs regardless of antigen, so switching antigen does not overcome it. Retrospective series, including SATEEN and BRE-354 at ESMO Breast 2026, show shorter progression-free survival for the second TOP1 ADC, particularly back-to-back; some data suggest an intervening chemotherapy restores sensitivity. Prospective sequencing trials are ongoing; see the ADC sequencing entry and the idea of payload-class switching.
Shares ADC sequencing, TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, A randomised trial of antibody-drug conjugate sequence in metastatic triple-negative breast cancer, Datopotamab deruxtecan.
Shares Datopotamab deruxtecan, Sacituzumab govitecan, Trastuzumab deruxtecan, Triple-negative breast cancer (TNBC).
Shares TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, Datopotamab deruxtecan, Sacituzumab govitecan, Triple-negative breast cancer (TNBC).
Shares TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, A randomised trial of antibody-drug conjugate sequence in metastatic triple-negative breast cancer, Datopotamab deruxtecan, Sacituzumab govitecan.
Shares TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, A randomised trial of antibody-drug conjugate sequence in metastatic triple-negative breast cancer, Sacituzumab govitecan, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem.
Shares TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, A randomised trial of antibody-drug conjugate sequence in metastatic triple-negative breast cancer, Datopotamab deruxtecan, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem.
Shares Sequential multiple-assignment randomised trials to find the best order of ADCs, ADC sequencing, HR-positive / HER2-negative breast cancer.
Shares Datopotamab deruxtecan, Sacituzumab govitecan, Trastuzumab deruxtecan, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem.